IMMUNOHISTOCHEMISTRY: PD-L1 CLONE 22C3 (DAKO)

PD-L1 (PROGRAMMED DEATH LIGAND 1) IS EXPRESSED ON TUMOR CELLS AND BINDS WITH PD-1 WHICH IS EXPRESSED ON IMMUNE CELLS. THIS INTERACTION HAMPERS THE IMMUNE RESPONSE AGAINST TUMOR CELLS. DRUGS HAVE BEEN DEVELOPED TO BLOCK THIS INTERACTION & BOOST THE IMMUNE RESPONSE. PD-L1 EXPRESSION IS USED TO GUIDE IMMUNOTHERAPY DECISIONS. CLONE 22C3 IS INDICATED AS A COMPANION DIAGNOSTIC AID IN IDENTIFYING PATIENTS FOR TREATMENT WITH PEMBROLIZUMAB IN THE FOLLOWING TUMORS : NON-SMALL CELL LUNG CARCINOMA (NSCLC), GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, CERVICAL CARCINOMA, UROTHELIAL CARCINOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) & ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC).